Rigel Pharmaceuticals, Inc. (RIGL) Reports Q3 Loss of $0.25
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts RIGL Hot Sheet
Price: $51.31 -0.27%
EPS Growth %: -34.9%
Financial Fact:
Contract revenues from collaborations: 3.76M
Today's EPS Names:
OPY, BNCC, ZVOI, More
EPS Growth %: -34.9%
Financial Fact:
Contract revenues from collaborations: 3.76M
Today's EPS Names:
OPY, BNCC, ZVOI, More
Join SI Premium – FREE
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) reported Q3 EPS of ($0.25), versus $0.96 reported last year. Revenue for the quarter came in at $4.35 million, versus $72.28 thousand reported last year.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Rigel Announces Conference Call and Webcast to Report Third Quarter 2026 Financial Results
- Cboe Global Markets (CBOE) Tops Q3 EPS by 21c
- Gates Industrial Corporation plc (GTES) Tops Q3 EPS by 4c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
